April 4, 2024
University of Cincinnati Cancer Center researchers will present abstracts at the American Association for Cancer Research annual meeting 2024, April 5-10 in San Diego, California.
October 25, 2022
National media outlets highlighted the results of the first-in-human trial of FLASH radiotherapy, led by University of Cincinnati Cancer Center researchers.
November 3, 2022
The University of Cincinnati's Trisha Wise-Draper, MD, PhD, is co-corresponding author of new research in JAMA Oncology that provides more clarity on how immunotherapy treatment for patients with cancer affects COVID-19 severity.
November 7, 2022
MSN India highlighted recent research led by the University of Cincinnati's Trisha Wise-Draper about how immunotherapy and immunosuppression affects COVID-19 severity.
November 15, 2022
The University of Cincinnati's Jeffrey Strawn led research that found in utero exposure to certain flame retardant chemicals may be a risk factor for developing anxiety symptoms in early adolescence.
April 12, 2022
The University of Cincinnati's Kyle Wang, MD, is the site principal investigator for the Trident trial, studying the effectiveness of earlier electrical treatment through Optune devices to treat glioblastomas.
June 6, 2022
The University of Cincinnati's Atsuo Sasaki and an international team of collaborators have been awarded a Human Frontier Science Program research grant to learn more about how cells migrate, with an ultimate goal of developing new treatments to prevent cancer growth and spread.
May 10, 2022
Research from the University of Cincinnati shows daily blueberry supplementation for certain middle-aged populations may lower the chances of developing late-life dementia.
April 5, 2022
The University of Cincinnati's Dr. Hyacinth I. Hyacinth is researching how different rates of cerebral small vessel disease and genetic differences contribute to higher rates of Alzheimer's disease and related dementias in non-Hispanic Black populations compared to non-Hispanic white patients.
June 10, 2022
The University of Cincinnati's Pier Paolo Scaglioni, MD, has received a $1.5 million National Cancer Institute grant to continue research into the roles of the KRAS gene and lipids in lung cancer.